{"title":"帕唑帕尼治疗期间出现严重的症状性心动过缓。","authors":"Cafer Zorkun, Öykü Alara Eren","doi":"10.5543/tkda.2024.03788","DOIUrl":null,"url":null,"abstract":"<p><p>Pazopanib, a tyrosine kinase inhibitor that targets growth factor receptors, is associated with various side effects, including bradycardia. We report a severe case of symptomatic bradycardia, with a heart rate dropping to 28 beats per minute, in a patient with cardiac angiosarcoma treated with 800 mg/day of pazopanib. Reducing the dosage to 600 mg/day improved the heart rate to 53 beats per minute. This case highlights the risk of severe bradycardia associated with pazopanib, emphasizing the need for vigilant heart rate monitoring.</p>","PeriodicalId":94261,"journal":{"name":"Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir","volume":"53 2","pages":"140-142"},"PeriodicalIF":0.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Symptomatic Severe Bradycardia during Pazopanib Treatment.\",\"authors\":\"Cafer Zorkun, Öykü Alara Eren\",\"doi\":\"10.5543/tkda.2024.03788\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Pazopanib, a tyrosine kinase inhibitor that targets growth factor receptors, is associated with various side effects, including bradycardia. We report a severe case of symptomatic bradycardia, with a heart rate dropping to 28 beats per minute, in a patient with cardiac angiosarcoma treated with 800 mg/day of pazopanib. Reducing the dosage to 600 mg/day improved the heart rate to 53 beats per minute. This case highlights the risk of severe bradycardia associated with pazopanib, emphasizing the need for vigilant heart rate monitoring.</p>\",\"PeriodicalId\":94261,\"journal\":{\"name\":\"Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir\",\"volume\":\"53 2\",\"pages\":\"140-142\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5543/tkda.2024.03788\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5543/tkda.2024.03788","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Symptomatic Severe Bradycardia during Pazopanib Treatment.
Pazopanib, a tyrosine kinase inhibitor that targets growth factor receptors, is associated with various side effects, including bradycardia. We report a severe case of symptomatic bradycardia, with a heart rate dropping to 28 beats per minute, in a patient with cardiac angiosarcoma treated with 800 mg/day of pazopanib. Reducing the dosage to 600 mg/day improved the heart rate to 53 beats per minute. This case highlights the risk of severe bradycardia associated with pazopanib, emphasizing the need for vigilant heart rate monitoring.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
